{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:14:19Z","timestamp":1792721659294,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec id=\"ab-coi250040-4\"><jats:title>Importance<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have improved overall survival in patients with advanced-stage cancers. However, data on their efficacy and safety in solid organ transplant recipients (SOTRs) are limited.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi250040-5\"><jats:title>Objective<\/jats:title><jats:p>To examine cancer-specific and patient survival among SOTRs with advanced-stage cancer receiving ICIs and identify factors associated with patient and graft outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi250040-6\"><jats:title>Data Sources<\/jats:title><jats:p>Electronic databases and clinical registries, including MEDLINE, Embase, ClinicalTrials.gov, Australia New Zealand clinical trials registry, and the World Health Organization International Clinical Trials Registry Platform, were searched from inception to June 2024 without language restriction.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi250040-7\"><jats:title>Study Selection<\/jats:title><jats:p>Case reports and series, observational studies, and clinical trials that described the treatment of advanced-stage cancers using ICIs in SOTRs were included.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi250040-8\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>Individual participant data were extracted and synthesized using a single-stage random-effect model.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi250040-9\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Time to cancer-related death was the primary outcome. The main secondary outcomes included time from ICI initiation to first rejection and cancer response according to Response Evaluation Criteria in Solid Tumors 1.1 criteria. Adjusted Cox proportional hazards regression models were conducted for time-to-event analyses.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi250040-10\"><jats:title>Results<\/jats:title><jats:p>Of 140 studies, 128 studies involving 343 SOTRs treated with ICI were included. Most participants were male (76.9%), kidney transplant recipients (70.9%), with a median (IQR) age of 63 years (14-88 years), and treated with programmed cell death protein-1 inhibitors (72.9%). Within 3 years of ICI initiation, 52.8% (95% CI, 43.9%-61.6%) died of cancers. Acute rejection occurred in 36.2% (95% CI, 30.7%-41.7%) at 1 year, and 18.4% (95% CI, 13.7%-23.1%) experienced graft loss at 1 year. Objective response at 1 year was 31.6% (95% CI, 25.0%-37.7%), with a higher response observed in patients with cutaneous squamous cell carcinoma (cSCC) (61.0% [95% CI, 45.5%-76.4%]) than melanoma (48.5% [95% CI, 26.8%-70.3%]), and other solid organ cancers (26.9% [95% CI, 14.5%-39.3%]). Transplant recipients with melanoma (hazard ratio [HR], 2.29; 95% CI, 1.31-3.99) and solid organ cancers (HR, 2.84; 95% CI, 1.70-4.74) experienced higher rates of cancer-related deaths than those with cSCC. Recipients with melanoma have a higher risk of acute rejection (HR, 2.88; 95% CI, 1.69-4.90) than cSCC. Maintenance with steroids and mammalian target of rapamycin inhibitors (mTORIs) was associated with a lower risk of rejection compared with other immunosuppressive agents (HR, 0.30; 95% CI, 0.14-0.63).<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi250040-11\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this study, cancer outcomes in SOTRs receiving ICIs varied by cancer type, with a higher probability of achieving response among those with cSCC than other cancers. Concurrent use of mTORIs and steroids during ICI therapy may reduce the risk of acute allograft rejection.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.2374","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:33:13Z","timestamp":1750638793000},"page":"1150","source":"Crossref","is-referenced-by-count":38,"title":["Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors"],"prefix":"10.1001","volume":"11","author":[{"given":"Nida","family":"Saleem","sequence":"first","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia"},{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"},{"name":"Department of Renal and Transplantation Medicine, Westmead Hospital, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Wang","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"},{"name":"Sydney School of Public Health, University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rejuso","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"},{"name":"Sydney School of Public Health, University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Teixeira-Pinto","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"},{"name":"Sydney School of Public Health, University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline H.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia"},{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Wilson","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Kieu","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Gately","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Prince Alexandria Hospital, Brisbane, Queensland, Australia"},{"name":"Australasian Kidney Trial Network, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Boroumand","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"},{"name":"Sydney School of Public Health, University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Chung","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billie","family":"Bonevski","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health, University of Sydney, New South Wales, Australia"},{"name":"Department of Medical Oncology, Westmead Hospital, New South Wales, Australia"},{"name":"Department of Medical Oncology, Blacktown Hospital, New South Wales, Australia"},{"name":"Melanoma Institute Australia, The Poche Centre, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Carroll","sequence":"additional","affiliation":[{"name":"Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia"},{"name":"Department of Health Sciences, University of South Australia, Adelaide, South Australia, Australia"},{"name":"Transplantation and Immunogenetics Service, Lifeblood, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai H.","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia"},{"name":"Faculty of Health and Medical Science, University of Western Australia, Perth, Australia"},{"name":"School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Craig","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germaine","family":"Wong","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, Kids Research Institute, The Children\u2019s Hospital at Westmead, New South Wales, Australia"},{"name":"Department of Renal and Transplantation Medicine, Westmead Hospital, New South Wales, Australia"},{"name":"Sydney School of Public Health, University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"coi250040r1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263210","article-title":"Trends in underlying causes of death in solid organ transplant recipients between 2010 and 2020: using the CLASS method for determining specific causes of death.","volume":"17","author":"S\u00f8borg","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"coi250040r2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1681\/ASN.2018090906","article-title":"Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant.","volume":"30","author":"Au","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"coi250040r3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients.","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"coi250040r4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2215\/CJN.14570920","article-title":"De novo malignancies after kidney transplantation.","volume":"17","author":"Al-Adra","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"coi250040r5","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/ijc.32585","article-title":"Cancer mortality in kidney transplant recipients: an Australian and New Zealand population-based cohort study, 1980-2013.","volume":"146","author":"Rosales","year":"2020","journal-title":"Int J Cancer"},{"issue":"8","key":"coi250040r6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients.","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"coi250040r7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015677","article-title":"Cancer in the transplant recipient.","volume":"3","author":"Chapman","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"coi250040r8","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy.","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"coi250040r9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227.","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi250040r10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma.","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"coi250040r11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae061","article-title":"Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.","volume":"17","author":"Van Meerhaeghe","year":"2024","journal-title":"Clin Kidney J"},{"issue":"1","key":"coi250040r12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"issue":"16","key":"coi250040r13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"coi250040r14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document.","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"coi250040r15","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool.","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"coi250040r16","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"coi250040r17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"coi250040r18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2288-9-57","article-title":"Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines.","volume":"9","author":"Marshall","year":"2009","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"coi250040r19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"coi250040r20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study.","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi250040r21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"coi250040r22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/LVT.0000000000000087","article-title":"Feasibility, safety, and outcome of second-line nivolumab\/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma.","volume":"29","author":"Di Marco","year":"2023","journal-title":"Liver Transpl"},{"issue":"9","key":"coi250040r23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma.","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi250040r24","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1002\/cncr.33134","article-title":"Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.","volume":"126","author":"Owoyemi","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"coi250040r25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers.","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250040r26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/lt.25887","article-title":"Graft programmed death ligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors.","volume":"27","author":"Shi","year":"2021","journal-title":"Liver Transpl"},{"key":"coi250040r27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686308","article-title":"Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single-center real-life experience from Italy.","volume":"11","author":"Strippoli","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"coi250040r28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma.","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"issue":"17","key":"coi250040r29","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.3390\/cancers15174312","article-title":"Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: real-world experience from a Canadian comprehensive cancer centre.","volume":"15","author":"Koch Hein","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16","key":"coi250040r30","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.3390\/cancers15164041","article-title":"PD-1 Inhibitors in elderly and immunocompromised patients with advanced or metastatic cutaneous squamous cell carcinoma.","volume":"15","author":"Yakobson","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"coi250040r31","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review.","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"issue":"17","key":"coi250040r32","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.3390\/cancers16173083","article-title":"Cutaneous squamous cell carcinoma in patients with solid-organ-transplant-associated immunosuppression.","volume":"16","author":"Khaddour","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"coi250040r33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ad.2020.11.005","article-title":"Melanoma in solid organ transplant recipients.","volume":"112","author":"Gonz\u00e1lez-Cruz","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"1","key":"coi250040r34","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/TP.0000000000003762","article-title":"Renal cell carcinoma and kidney transplantation: a narrative review.","volume":"106","author":"Dahle","year":"2022","journal-title":"Transplantation"},{"issue":"5","key":"coi250040r35","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1002\/cam4.5394","article-title":"Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system.","volume":"12","author":"Cui","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"coi250040r36","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41467-023-37230-4","article-title":"Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy.","volume":"14","author":"Dunlap","year":"2023","journal-title":"Nat Commun"},{"issue":"7","key":"coi250040r37","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune checkpoint inhibitors in solid organ transplant recipients with advanced skin cancers\u2014emerging strategies for clinical management.","volume":"107","author":"Ferr\u00e1ndiz-Pulido","year":"2023","journal-title":"Transplantation"},{"issue":"4","key":"coi250040r38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12539-021-00437-4","article-title":"Application of immune checkpoint inhibitors in solid organ transplantation recipients: a systematic review.","volume":"13","author":"Miao","year":"2021","journal-title":"Interdiscip Sci"},{"issue":"1","key":"coi250040r39","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"coi250040r40","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29360","article-title":"Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1.","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2835689\/jamaoncology_saleem_2025_oi_250040_1759848044.99156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:01:26Z","timestamp":1760626886000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2835689"}},"subtitle":["A Systematic Review and Individual Participant Data Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.2374","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}